Brief: Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States
17/07/2025 12:58
Harrow Inc HROW.O: HARROW ENTERS INTO COMMERCIALIZATION AGREEMENT WITH SAMSUNG BIOEPIS FOR OPHTHALMOLOGY BIOSIMILARS PORTFOLIO IN THE UNITED STATES HARROW INC - TO ASSUME COMMERCIAL RESPONSIBILITY FOR BYOOVIZ AND OPUVIZ BY 2025 HARROW INC - GAINS EXCLUSIVE U.S. RIGHTS TO OPHTHALMIC BIOSIMILARS Source text: ID:nBw50L9sga Further company coverage: HROW.O
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates